The 2019 Penta guidelines for first and second line antiretroviral treatment are now available.
A table with guidance on dosing and use of paediatric formulations is also provided. This is produced and updated regularly by members of the Penta guidelines group. It should be noted that this guidance table provides some dosing recommendations outside of current European licensing. Local policy for use of unlicensed medication and dosing should be followed if this is the case and required.*
The aim of these guidelines is to provide a concise reference document to guide antiretroviral choices for children and adolescents with perinatally acquired HIV in the European region. This document will be updated at regular intervals by the Penta guidelines group or as significant new data or evidence becomes available.
A document summarising responses to the public consultation and writing group conflict of interest statements are available on request from email@example.com.
30th April, 2021
*The table is intended for use in conjunction with detailed antiretroviral drug information available from EMA and FDA websites and is aimed at practioners experiences in paediatric HIV care. Its aim is to provide a practical guide to prescribing in the clinic. Please note that drug information rapidly changes and it is ultimately the responsibility of the treating clinician to check validity of information provided before prescribing.